| アブストラクト | INTRODUCTION: Use of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) has significantly increased due to their cardiovascular benefits. Whether SGLT-2is increase risk of cancer has been of concern since first clinical trials, but this question remains unclear because of methodological limitations in previous studies. METHODS: We conducted a disproportionality analysis using Vigibase((R)) between 2014 and 2023 to estimate the association between SGLT-2i use and the risk of reporting of different subtypes of cancers, compared with glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors. RESULTS: Among 644 reported cases of cancer associated with SGLT-2i use, 427 (66.3%) were male, with a mean age of 66.5 +/- 9.7 years. Sodium-glucose cotransporter 2 inhibitors showed increased reporting odds ratio for bladder cancer (ROR 4.46, 95% CI 3.23-6.17) and kidney cancer (ROR 1.84, 95% CI 1.25-2.69), but not for all other cancer subtypes. CONCLUSION: In this disproportionality analysis with a hypothesis-generating approach, SGLT-2is are associated with an increased risk of reporting bladder and kidney cancer. There is a need of an urgent clarification of this signal with further long-term observational studies. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2025/4/15 |
|---|
| 投稿者 | Gautier, Paul; Elbaz, Meyer; Bouisset, Frederic; Despas, Fabien; Montastruc, Francois |
|---|
| 組織名 | Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of;PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU),;37 Allees Jules Guesde, 31000, Toulouse, France.;Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Centre;d'Investigation Clinique 1436, Toulouse University Hospital, Toulouse, France.;Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse,;31059, Toulouse, France.;francois.montastruc@univ-tlse3.fr. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40232585/ |
|---|
